University of Illinois Cancer Center: Summer CME SeriesSession 1 - Breast Cancer | June 11, 2025Pre-Test UICMES | Session 1 | Pre-Test | June 11, 2025 Name * Name First First Last Last Email * 1. Which of the following therapies is most commonly used as adjuvant treatment in early-stage HER2+ breast cancer? * A. Tamoxifen B. Trastuzumab C. Atezolizumab D. Olaparib 2. What is a key clinical distinction in selecting therapy for ER+HER2– metastatic breast cancer? * A. All ER+ patients should receive chemotherapy first B. HER2 testing is not required C. Endocrine resistance and genomic profiling inform treatment D. Immunotherapy is first-line for ER+ disease 3. Which biomarker is most relevant for selecting patients for sacituzumab govitecan in triple-negative breast cancer (TNBC)? * A. BRCA mutation B. PD-L1 expression C. Trop-2 expression D. ESR1 mutation 4. A primary challenge in treatment sequencing for metastatic breast cancer includes: * A. Selecting chemotherapy based on age only B. Ignoring progression-free survival data C. Balancing prior therapies and patient tolerance D. Treating all subtypes the same 5. (Patient Case). A 48-year-old woman with newly diagnosed metastatic TNBC is PD-L1 positive and has high Trop-2 expression. She previously received dose-dense AC-T in early-stage disease 3 years ago. Based on current data, which regimen is most appropriate as first-line therapy? * A. Capecitabine monotherapy B. Atezolizumab plus nab-paclitaxel C. Sacituzumab govitecan D. Tamoxifen Submit Pre-Test
